A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2018
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 05 Sep 2018 Planned End Date changed from 1 Oct 2019 to 24 Aug 2020.
- 05 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 24 Aug 2020.
- 31 Aug 2018 Biomarkers information updated